drugset / Trial / NCT04089150
MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
Phase 2
Unknown
120 enrolled
Australasian Gastro-Intestinal Trials Group
Australian Government Department of Health and Ageing · collabTrans Tasman Radiation Oncology Group · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, multicentre randomised, phase II clinical trial, with randomisation 2:1 by minimisation and stratification by tumour stage, planned chemotherapy and institution.
Timeline
- Start
- 2019-10-01
- Primary completion
- 2023-05
- Completion
- 2023-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Capecitabine | Small molecule | 830 mg/m2 | Oral |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Irinotecan | Small molecule | 150 mg/m2 | — |
| Background | Leucovorin | Small molecule | 50 mg | — |
| Background | Nab-paclitaxel | Small molecule | 125 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |